Skip to main content

Andrew Berchuck, MD

Andrew Berchuck, MD
James M. Ingram Distinguished Professor of Gynecologic Oncology
Campus Mail: 25171 Morris Bldg, Durham, NC 27710
Phone: (919) 684-3765
Email: berch001@mc.duke.edu

Dr. Andrew Berchuck is Director of the Duke Division of Gynecologic Oncology and holds the James M. Ingram Distinguished Professorship. He is a practicing oncologist who is actively involved in the surgical and chemotherapy management of women with ovarian, endometrial and lower genital tract cancers. This includes minimally invasive laparoscopic surgical approaches. He also has developed a research program that focuses on the molecular-genetic alterations involved in malignant transformation of the ovarian and endometrial epithelium. He has published over 300 peer-reviewed papers in these areas. The objectives of his research include 1) identification of ovarian cancer susceptibility polymorphisms through a population-based case-control molecular epidemiologic study, and 2) use of genomic approaches  to elucidate the molecular heterogenetity of ovarian cancer. Thirty fellows and residents have worked in his lab, several of whom are now funded investigators. His research efforts have been recognized nationally and he has received awards for best oral presentation at the annual meetings of both the Society of Gynecologic Oncology and the International Gynecologic Cancer Society. Dr. Berchuck was awarded the Barbara Thomason Ovarian Cancer Research Professorship by the American Cancer Society in 2006. He has served as editor of several books in the field including Principles and Practice of Gynecologic Oncology. Dr. Berchuck also has a major commitment to national activities, and was President of the Society of Gynecologic Oncology in 2008. He served as chair of the scientific advisory committee of the Ovarian Cancer Research Fund (http://www.ocrf.org) in New York City. Finally, he is also head of the steering committee of the international Ovarian Cancer Association Consortium (OCAC), a group of 50 case-control studies that are working together to identify ovarian cancer susceptibility polymorphisms (www.srl.cam.ac.uk/consortia/ocac/index.html).

Education and Training

  • M.D., Case Western Reserve University, 1980

Research

Dr Berchuck is interested in the molecular pathogenesis of ovarian and endometrial cancer. 

View Publications

Selected Grants and Awards

Publications

Gonzalez, Rafael, Laura J. Havrilesky, Evan R. Myers, Angeles Alvarez Secord, Joseph A. Dottino, Andrew Berchuck, and Haley A. Moss. “Cost-effectiveness analysis comparing "PARP inhibitors-for-all" to the biomarker-directed use of PARP inhibitor maintenance therapy for newly diagnosed advanced stage ovarian cancer.” Gynecol Oncol 159, no. 2 (November 2020): 483–90. https://doi.org/10.1016/j.ygyno.2020.08.003.

Full Text

Talhouk, Aline, Joshy George, Chen Wang, Timothy Budden, Tuan Zea Tan, Derek S. Chiu, Stefan Kommoss, et al. “Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).” Clin Cancer Res 26, no. 20 (October 15, 2020): 5411–23. https://doi.org/10.1158/1078-0432.CCR-20-0103.

Full Text

Watson, Catherine H., Lindsay Soo, Brittany A. Davidson, Laura J. Havrilesky, Paula S. Lee, Leah J. McNally, Rebecca A. Previs, Angeles Alvarez Secord, Andrew Berchuck, and Noah D. Kauff. “Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices.” Int J Gynecol Cancer 30, no. 10 (October 2020): 1583–88. https://doi.org/10.1136/ijgc-2020-001536.

Full Text

Ong, Jue-Sheng, Eske M. Derks, Mikael Eriksson, Jiyuan An, Liang-Dar Hwang, Douglas F. Easton, Paul P. Pharoah, et al. “Evaluating the role of alcohol consumption in breast and ovarian cancer susceptibility using population-based cohort studies and two-sample Mendelian randomization analyses.” Int J Cancer, September 25, 2020. https://doi.org/10.1002/ijc.33308.

Full Text

Modugno, Francesmary, Zhuxuan Fu, Susan J. Jordan, Aocs Group, Jenny Chang-Claude, Renée T. Fortner, Marc T. Goodman, et al. “Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 case-control studies.” Eur J Epidemiol, September 21, 2020. https://doi.org/10.1007/s10654-020-00682-9.

Full Text

Brieger, Katharine K., Siri Peterson, Alice W. Lee, Bhramar Mukherjee, Kelly M. Bakulski, Aliya Alimujiang, Hoda Anton-Culver, et al. “Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival.” Gynecol Oncol 158, no. 3 (September 2020): 702–9. https://doi.org/10.1016/j.ygyno.2020.06.481.

Full Text

Zhang, Yan Dora, Amber N. Hurson, Haoyu Zhang, Parichoy Pal Choudhury, Douglas F. Easton, Roger L. Milne, Jacques Simard, et al. “Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers.” Nat Commun 11, no. 1 (July 3, 2020): 3353. https://doi.org/10.1038/s41467-020-16483-3.

Full Text

Song, Honglin, Ed M. Dicks, Jonathan Tyrer, Maria Intermaggio, Georgia Chenevix-Trench, David D. Bowtell, Nadia Traficante, et al. “Population-based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high-grade serous ovarian cancer.” J Med Genet, June 16, 2020. https://doi.org/10.1136/jmedgenet-2019-106739.

Full Text

Manichaikul, Ani, Lauren C. Peres, Xin-Qun Wang, Mollie E. Barnard, Deanna Chyn, Xin Sheng, Zhaohui Du, et al. “Identification of novel epithelial ovarian cancer loci in women of African ancestry.” Int J Cancer 146, no. 11 (June 1, 2020): 2987–98. https://doi.org/10.1002/ijc.32653.

Full Text

Lee, Alice W., Anna H. Wu, Ashley Wiensch, Bhramar Mukherjee, Kathryn L. Terry, Holly R. Harris, Michael E. Carney, et al. “Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored.” Epidemiology (Cambridge, Mass.) 31, no. 3 (May 2020): 402–8. https://doi.org/10.1097/ede.0000000000001175.

Full Text

Pages